Single Cell Leukocyte Landscapes and Cardiovascular Risk in Children With Chronic Kidney Disease
- Conditions
- Chronic Kidney DiseasesAgingCardiovascular DiseasesMicrobial Colonization
- Interventions
- Other: No intervention
- Registration Number
- NCT04976010
- Lead Sponsor
- Charite University, Berlin, Germany
- Brief Summary
Chronic kidney disease (CKD) is associated with an increased cardiovascular mortality. In particular children with early-onset CKD have a lifelong increased risk to suffer from cardiovascular disease (CVD). Therefore, children with CKD deserve our attention. The immune system in children with CKD is disturbed, exhibiting pro-inflammatory features. Therefore, we aim to learn more about the characteristics of the immune system in early-onset CKD. In this project PBMC of pediatric CKD patients and age-matched healthy controls will be analysed and compared using CITE-Seq as a multimodal scRNAseq phenotyping method. All patients will be clinically characterized to integrate cardiovascular and immunological data.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 38
- matching to one of the following groups CKD G3-5: estimated eGFR according to Schwartz formula <60ml/min*1,73m2 (no ESKD) CKD G5 D: patients with ESKD treated with hemodialysis for at least 3 months normal kidney function: CKD G1 or no CKD with eGFR > 90ml/min*1,73m2
- informed consent to participate in this study
- body weight of less than 15kg
- acute or chronic inflammatory diseases
- fever
- diabetes
- chronic liver disease
- inflammatory bowel disease or other gastrointestinal disorders (constipation, diarrhea, short bowel syndrome)
- antibiotic prophylaxis or treatment within four weeks prior to recruitment
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Normal kidney function No intervention Patients enrolled with normal kidney function and/or CKD G1 and an estimated eGFR \> 90ml/min CKD G3-5 No intervention Patients with CKD and an estimated eGFR \< 60ml/min not yet on dialysis End stage kidney disease (ESKD) CKD G5 Hemodialysis No intervention Patients on hemodialysis for at least 3 months
- Primary Outcome Measures
Name Time Method Immunephenotyping of human PBMC at recruitment scRNAseq with Cellular Indexing of Transcriptomes and Epitopes (CITE)-Seq for whole PBMC will be used to gain information on single cell transcriptomes across multiple immune cell populations together with expression levels of classical mmunological surface markers.
- Secondary Outcome Measures
Name Time Method Microbiome sequencing of fecal samples at recruitment 16S RNA amplicon sequencing and whole genome shotgun sequencing will be perfomred in fecal samples, collected in RNA/DNA shield. This will allow us insights in composition (abundances) and function of the gut microbiome.
Pulse wave velocity at recruitment The pulse wave velocity (m/s) will be measured in all recruited patients by usinfg the Mobilograph. Data will be normalized to age.
Echocardiography at recruitment A basic echocardiography will be conducted evaluating diastolic and systolic, right and left ventricular function parameters.
Targeted metabolomics of plasma samples at recruitment By using liquid-chromatography (LC) and gas-chromatography (GC) mass-spectrometry plasma samples will be analyzed for tryptophan metabolites and short chain fatty acids (absolute quantifiaction in µM).
Carotid intima media thickness at recruitment The carotid intima media thickness (mm) will be measured using ultrasound imaging of the carotid vessel. Data will be normalized to age.
Trial Locations
- Locations (1)
Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité-Universitätsmedizin Berlin
🇩🇪Berlin, Germany